C3591031
Проводит Пфайзер Инк.
Страница компанииREAL-WORLD OBSERVATIONAL STUDY OF ZAVICEFTA (REGISTERED) (CEFTAZIDIME-AVIBACTAM) TO CHARACTERIZE USE PATTERNS, EFFECTIVENESS AND SAFETY - EZTEAM STUDY
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03923426/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 572 чел. во всех странах исследования.
- Центров в реестре: 6 в 4 городах. Список — ниже на странице.
- Плановая дата окончания (03.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 4
Критерии включения
- Hospitalized patient ≥18 years old or considered an adult in accordance with the age of majority in the participant's country of residence at the time of treatment with ceftazidime-avibactam.
- Patient received ≥1 dose of ceftazidime-avibactam in routine practice at participating site since 01 January, 2018 onwards or since the date of launch in the country if it is after 01 January, 2018.
- Patient underwent microbiologic sampling ≤5 days before the initiation of ceftazidime-avibactam (irrespective of results and actual bacteriological identification).
- Patient has all required essential data elements which include:
- Start and stop dates of ceftazidime-avibactam,
- Start and stop dates of prior antibiotic therapy used for the index infection,
- Type of combined antibiotic therapy (if applicable) and start and stop dates of any antibiotic combined with ceftazidime-avibactam.
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study where required by local regulations.
Критерии невключения
- Patients must not meet any of the following exclusion criteria to be eligible:
- The patient is enrolled in any clinical trial of an investigational product. Patients who are enrolled in non-interventional studies (NISs) (e.g. registries) are eligible for inclusion.
- The patient has received ceftazidime-avibactam in a compassionate care program setting.
- The patient was exposed to ceftazidime-avibactam before use for the index infection.
Источник: ClinicalTrials.gov, NCT03923426 · запись обновлена в реестре 21 июня 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (10)
- Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS 72+ Population — From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS72- Population — From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Total and Daily Dose of Ceftazidime-Avibactam: FAS72+ Population — From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Total and Daily Dose of Ceftazidime-Avibactam: FAS72- Population — From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Number of Participants Classified According to Frequency of Dosing: FAS72+ Population — From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Number of Participants Classified According to Frequency of Dosing: FAS72- Population — From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Total Duration of Administration of Ceftazidime-Avibactam: FAS72+ Population — From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Total Duration of Administration of Ceftazidime-Avibactam: FAS72- Population — From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72+ Population — From start of index treatment to end of index treatment (maximum 179 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
- Number of Participants Classified According to Reason for Discontinuation of Ceftazidime-Avibactam: FAS72- Population — From start of index treatment to end of index treatment (maximum 3 days of treatment exposure) (from the data evaluated in approximately 40 months of the study)
Цель исследования
This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 12 countries (including but not limited to Austria, France, Germany, Greece, Italy, Spain, United Kingdom, Russia, Argentina, Colombia, Brazil, and Mexico), with possible expansion to other countries as ceftazidime-avibactam is launched. Eligible patients are adults who have been treated with ceftazidime-avibactam in routine practice at participating sites since 01 January, 2018 onwards or since the date of launch in the country if it is posterior to 01 January, 2018. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
Где проходит
6 центров в 4 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03923426 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.